Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper

Science Translational Medicine, Journal Year: 2022, Volume and Issue: 14(650)

Published: June 22, 2022

Increased orexin/hypocretin signaling is implicated in opioid withdrawal, sleep disturbances, and drug-seeking behaviors. This study examined whether a dual-orexin receptor antagonist would improve withdrawal outcomes when compared with placebo during buprenorphine/naloxone taper. Thirty-eight participants use disorder were recruited to clinical research unit maintained on 8/2 16/4 mg of treatment for 3 days before being randomized 20 suvorexant ( n = 14), 40 12), or 12); 26 individuals completed the study. After randomization, underwent 4-day taper post-taper observation period. Total time (TST) was collected nightly wireless electroencephalography device wrist-worn actigraphy; symptoms assessed via Subjective Opiate Withdrawal Scale (SOWS); abuse potential 0- 100-point visual analog scale “High” every morning. A priori included two-group (collapsing doses versus placebo) three-group comparisons area-under-the-curve (AUC) scores TST, SOWS, High. In comparisons, receiving displayed increased TST decreased SOWS AUC taper, but there no difference among groups. There evidence two- analyses. The results suggest that might be promising undergoing

Language: Английский

---

Pharmacological and Nonpharmacological Interventions to Address Sleep Disturbance in Substance use Disorders

Current Sleep Medicine Reports, Journal Year: 2025, Volume and Issue: 11(1)

Published: Jan. 29, 2025

Language: Английский

---

Probing different paradigms of morphine withdrawal on sleep behavior in male and female C57BL/6J mice

Behavioural Brain Research, Journal Year: 2023, Volume and Issue: 448, P. 114441 - 114441

Published: April 18, 2023

Language: Английский

---

Suvorexant alters dynamics of the sleep-electroencephalography-power spectrum and depressive-symptom trajectories during inpatient opioid withdrawal

SLEEP, Journal Year: 2024, Volume and Issue: 47(4)

Published: Jan. 30, 2024

Abstract Study Objectives Opioid withdrawal is an aversive experience that often exacerbates depressive symptoms and poor sleep. The aims of the present study were to examine effects suvorexant on oscillatory sleep-electroencephalography (EEG) band power during medically managed opioid withdrawal, their association with severity symptoms. Methods Participants use disorder (N = 38: age-range:21–63, 87% male, 45% white) underwent 11-day buprenorphine taper, in which they randomly assigned (20 mg [n 14] or 40 12]), placebo 12], while ambulatory sleep-EEG data was collected. Linear mixed-effect models used explore: (1) main interactive drug group, time power, (2) associations between change, symptoms, severity. Results Oscillatory spectral tended be greater groups. Over course study, decreases delta observed all groups (β −189.082, d −0.522, p <0.005), increases beta mg: β 2.579, 0.413, 0.009 | 5.265, 0.847, < 0.001) alpha 158.304, 0.397, 250.212, 0.601, sigma 48.97, 0.410, 0.001 71.54, 0.568, two During four-night associated 190.90, 0.308, 0.99 433.33, 0.889 <0.001), 215.55, 0.034, 0.006 192.64, −0.854, both −357.84, −0.659, 0.004 −906.35, −1.053, <0.001). Post-taper 740.58, 0.964 <0.001 662.23, 0.882, <0.001) only: 335.54, 0.560, 0.023) reduced group. Conclusions highlight a complex nuanced relationship depression withdrawal. Changes may represent mechanism influencing

Language: Английский

---

Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(6), P. e0304461 - e0304461

Published: June 13, 2024

Insomnia symptoms are negatively related to opioid use disorder (OUD) treatment outcomes, possibly reflecting the influence of sleep on neurofunctional domains implicated in addiction. Moreover, intersection between OUD recovery and represents an area well-suited for development novel, personalized strategies. This study assessed prevalence clinically significant insomnia characterized its correlates among a clinical sample adults with receiving buprenorphine.

Language: Английский

---

Trazodone in the treatment of chemical addictions

V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, Journal Year: 2025, Volume and Issue: 59(1), P. 81 - 89

Published: March 28, 2025

Trazodone is an FDA-approved antidepressant used to treat depression. However, mental health professionals also use it various psychiatric and medical conditions, including substance disorders, which have FDA- not approved indications. The problem of addiction these substances important part modern care. Among all the risk factors for premature death, tobacco ranks second, while alcohol seventh. Direct exposure their negative effects contribute significantly mortality. Thus, issue proper treatment disorders associated with remains relevant. has been shown antagonistic on serotonin receptors (5-HT2) a reuptake inhibitor. It demonstrated be effective in individuals alcohol, benzodiazepine, opiate addictions, as well other dependencies. Although exact mechanism trazodone’s action body fully understood, its advantage lies relatively low number side compared medications. Despite this, trazodone may suitable option improving depressive symptoms sleep issues patients, potentially reducing relapsing into abuse.

Language: Английский

---

Teens and opioids postsurgery (TOPS): protocol for a prospective observational study describing associations between sleep deficiency and opioid use following outpatient surgery in adolescents

BMJ Open, Journal Year: 2025, Volume and Issue: 15(4), P. e099679 - e099679

Published: April 1, 2025

Introduction The opioid crisis is a significant burden on adolescent public health in the USA. Medical use of prescription opioids pathway via which adolescents transition to misuse, disorder and overdose. More than half all prescribed are for pain management following surgery. Yet, little known about critical period surgery during initiate misuse or modifiable mechanisms (such as sleep deficiency) contributing this process. This prospective observational study will broaden our knowledge by examining associations between deficiency We also examine behavioural, psychological, family social factors linking with misuse. Methods analysis Adolescents (10–19 years) undergoing outpatient orthopaedic surgery, along one parent, be recruited from two paediatric hospitals, sample 400 dyads. assessed at six timepoints. Before participants undergo comprehensive multimodal assessments (sleep surveys actigraphy). Participants report previous substance use, intensity psychosocial, factors. then closely monitored over first 14 days using ecological momentary assessment methods capture real-time, naturalistic, daily data sleep, psychological (including mood, affect subjective response use). Opioid (total number doses duration) measured an innovative electronic medication monitoring device Follow-up 3 months, 6 12 months 24 track development time. Our primary outcomes include immediate presence after Multilevel mediation models determine predictor variables acute postsurgical use. apply modern machine learning algorithms develop validate predicting Ethics dissemination was approved Advarra’s Center Institutional Review Board Intelligence (CIRBI) (Protocol 00072049), serves single IRB record multisite study.

Language: Английский

---

Perspectives and experiences with sleep and recovery among women receiving buprenorphine for opioid use disorder

PLOS mental health., Journal Year: 2025, Volume and Issue: 2(4), P. e0000250 - e0000250

Published: April 8, 2025

Sleep issues are prevalent among women receiving medication for opioid use disorder (OUD). However, there is limited data about subjective sleep experiences and how they relate to OUD trajectories. This mixed-methods study explored the intersection of recovery from patient perspective a sample OUD. enrolled non-pregnant aged 18-65 who were stabilized on buprenorphine an outpatient program. Participants recruited during their routine treatment visits, enrollment occurred February 2022 through September 2023. Study participants endorsed clinically elevated insomnia symptoms Insomnia Severity Index (ISI) (≥11 score) (n=50) included in current analyses. A sub-sample (n=11) met ISI threshold participated semi-structured interviews. Survey responses analyzed using descriptive statistics, interviews applied thematic analysis. The average length time overall was 30 months (range: 2 – 245 months). reported engagement healthy behaviors, grouped into four domains: positive related cognitions, environment, restriction, reducing stimulating activities. Respondents characterized multidimensional relationship between health. Women also described evolves addiction recovery, good reduces risk return substance use. Finally, discussed impacts that have sleep, specifically might align with it impact energy levels. We found dynamic process this Findings intended inform future investigations mechanisms underlying sleep-OUD intersection. In addition, reflects importance incorporating perspectives development therapeutics targeting population.

Language: Английский

---

Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder

Expert Opinion on Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: May 14, 2025

A critical challenge in providing effective medical care for individuals opioid agonist treatment (OAT) use disorder is the management of acute and chronic pain. While pain commonly co-occurs with disorder, there limited research to guide this population. We first provide an overview etiology pain, highlighting areas complexity patients receiving OAT. then describe search strategy, which involved a date-inclusive relevant terms PubMed, EMBASE, Cochrane Central Register Controlled Trials. After summarizing results on evidence pharmacological behavioral treatments OAT, we conclude discussion these finding summarized expert opinion state evidence. The suggests that while OAT limited, promising work ongoing translate existing treatments, particularly support However, further warranted, regarding options.

Language: Английский

---

Sleep in Patients With Substance Use Disorders

Oxford University Press eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 1219 - 1245

Published: May 22, 2025

Abstract There is a bidirectional relationship between substance use disorders and sleep disturbances. Substance misuse, including chronic of alcohol, cannabis, opioids, cocaine, impacts both the subjective quality objective measures sleep. In turn, disturbances, insomnia, have been linked to initiation, maintenance, relapse disorder. This chapter summarizes recent research findings on characteristics disturbances among individuals with disorders. It then discusses available tools aid clinicians in diagnosing their patients. Finally, it outlines key options considerations for non-pharmacological pharmacological treatments disorder population.

Language: Английский

---